In the Review entitled “Pharmacological small molecules for the treatment of lysosomal storage disorders” by BE Smid, JMFG Aerts, RG Boot, GE Linthorst & CEM Hollak, published in the November 2010 issue of Expert Opinion on Investigational Drugs (Expert Opin. Investig. Drugs (2010) 19(11):1367-1379), it has been brought to the authors' attention that there was an error in Section 2.1.2 on page 1370.
The first two sentences of the second paragraph should have read as follows:
Phase II study in GD type 1 patients, eliglustat showed significant improvements of hemoglobin and platelet counts, hepatosplenomegaly, biochemical markers and bone mineral density. Gastrointestinal side effects were infrequent and 2 patients (out of 26 patients) had a non-sustained ventricular tachycardia which was considered unrelated to treatment [70].
The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.